Metastatic pancreatic ductal adenocarcinoma pancreatic (PDAC) is characterized by poor prognosis and short survival. Today, the use of new polytherapeutic regimens increases clinical outcome of these patients opening new clinical scenario.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most important issues in the context of cancer being the fourth leading cause of death in USA and the sixth in Europe and Japan [1] [2] with a 5-year survival no greater than 6% [2] and an estimated increase in incidence that will bring it to the second leading cause of cancer death in 2030 [3] . At first diagnosis, only 10%-20% of PDAC patients present with primarily resectable disease. whereas, approximately 60% of patients are affected by metastatic disease [4] Today, according to international guidelines, distant metastases (including non regional lymph nodes) and vascular infiltration are absolute contraindication to surgery [5] . Surgical resection of PDAC with synchronous distant metastases is not indicated as the average survival time appears equivalent to that of chemotherapy alone [6] .
In the past, in the absence of active primary chemotherapy regimens, many surgeons attempted to resect liver or lymph node metastasis in a single operation or in two different times after resection of the primary with detrimental results in terms of survival and quality of life [7] .
Today, the use of polychemotherapy regimens increases the chemosensitivity and the rate of response to the disease. In a Phase III randomized study, the combination chemotherapy FOLFIRINOX gained a significant advantage in terms of progression free survival (PFS) (6.4 months versus 3.3 months; p <0.0001) and overall survival (OS) (11.1 months versus 6.8 months, 1-y OS versus 48.4% 20.6% p <0.0001) compared to gemcitabine in patients with metastatic disease and age ≤70 years [8] . Furthermore, another randomized phase III study of 861 patients with mPDAC previously untreated have shown that the combination gemcitabine-nabpaclitaxel can improve PFS (HR 0.69; p <0.0001) and OS (HR 0.72; p <0.0001) compared to gemcitabine alone [9] .
A crucial issue related to the actual improvement achieved with these new regimens is represented by the occasional possibility to observe a radiological complete response of metastatic lesions in patients with synchronous primary tumor [10] . What could be the best therapeutic management of these patients? Could surgery represent an indication? Herein, we discuss the role of surgery in a long term metastatic PDAC survivor who presented a complete response of synchronous liver metastases after modified FOLFIRINOX regimen.
Case report
A Caucasian 64-year-old man suffering from hypertension and diabetes presented with an history of abdominal pain in the last two months. A computer tomography (CT) scan of abdomen revealed a lesion of 4 cm in diameter localized in the head of pancreas ( Figure 1A events were diarrea, stomatitis, and anemia. Occasionally, grade 3 neutropenia, anemia, diarrhea, and fatigue required dosage adaptions. After, a second line with gemcitabine was administred for 6 months due to the increase of liver and lung metastases. Globally, the patient achieved an OS of 45 months.
Patient Record
Treatment courses and clinical features of this patient were collected at the National Cancer
Institute "Giovanni Paolo II" of Bari, Italy. The patient signed an informed consent for the study which was approved by the local Ethical Committee (n° 424 of 2013).
Discussion
Liver metastases strongly impact PDAC outcome and embody an unmet clinical need target, representing one of the main morbidity and mortality factors in these patients. However, sometimes liver metastases are sensitive to chemotherapy treatment due to greater drug delivery than pancreatic tissue [12] . Unfortunately, the complete radiological response to liver metastases is not supported by high quality literature data able to drive the specialist trough a given clinicaljudgment-based therapeutic decision [13] .
Indeed, only scanty evidences derived from case reports and retrospective analyses have been published to date [14] . Limitations of these studies are the retrospective methodology employed, the population heterogeneity, the difference between the surgery volume of the referral centers involved and the lack of homogeneity of the primary cytoreductive therapy utilized. Moreover, the concordance between experts in the field is also insufficient. Despite the available evidences do not support upfront synchronous resection of PDAC liver metastases, conversion surgery after optimal response to chemotherapy justifies a reasonable optimism for such integrated therapeutic window [14] . It is rational to include our case clinical course within the PDAC phenotype identified by Frigerio et al., in which the complete response obtained on liver metastases to a first line cytoreduction, might predict a favorable clinical outcome with a median overall survival (OS) of 56 months for 24 out of 535 subjects (4,5%) bridged to surgery. The regimen employed was either FOLFIRINOX (66%) or gemcitabine-based therapy (34%) [15] , leading to 88% of R0 resection and to 17% of patients gaining a complete pathological response. The mortality rate was 0%.
Furthermore, also primary tumor excision along with synchronous metastatic surgical resection for 23 patients out of 1147 (2%) in optimal response after either FOLFIRINOX (61%) or gemcitabinebased therapy (39%), showed a median OS of 34.1 months [16] . In light of the aforementioned data further reports confirmed analogous clinical behavior [17] .
Analogous reports are derived from Crippa et al. [18] , who published the results of a retrospective Conversely, some Authors showed that synchronous pancreatic and liver metastases resection upfront did not result in improved survival compared to palliative treatment (mOS range of 6 months) and does not appear to be justified [19] [20] .
Other evidences reported a small increase in survival for resection of synchronous PDAC liver metastases with acceptable safety in highly selected patients [21] [22] . Hackert et al. published the results of a single-center retrospective study in which postoperative complications and survival were evaluated in 62 patients with PDAC with synchronous liver metastases undergoing pancreatic and hepatic primary surgical resection. Patients suffered from limited liver disease (oligometastatic pancreatic cancer) and in 57 patients an atypical liver resection of one or two metastases was performed. About 10% of patients developed a clinically significant pancreatic fistula, 6.4% postoperative bleeding; 3.2% of patients underwent second-surgery and 30-day mortality was 1.6%.
Median OS was 12.3 months and 5-year survival was 8.1%. Limitations of this study consisted of retrospective analysis and the lack of complete data regarding the adjuvant treatment employed [23] .
Therefore, according to current evidences it is reasonable to suggest that in patients with liver oligometastatic PDAC cancer, surgery upfront indication would necessitate prospective controlled clinical trials to support clinical decisions.
Conversely, surgical treatment can be considered in highly selected metastatic PDAC cases with stringent response to primary chemotherapy in clinical trials at reference centers. However, to date there are no selection criteria for primitive or liver metastasis resection of mPDAC.
Given the presented elements it would be of paramount importance to identify two orders of criteria aimed to proper tailor the combination approach to mPDAC: biologic predictors might foster a personalized therapeutic plan and imaging criteria, able to resolve the response criteria dilemma, hold the promise to dissect the potential cure rate of a given patient subgroup. In some carefully selected cases after primary chemotherapy, the objective response assessment by imaging and tumor-markers can orientate the surgery choice.
Our case report highlights an extraordinary and apparently unpredictable disease course, arising unsolved clinical and pre-clinical question. Given that the complete response of hepatic metastasis in PDAC constitutes a rare event, an extensive biologic investigation can help to deeper characterize the underlying unsolved biologic phenotype. The genomic landscape appears to be one of the major challenging factors driving tumor heterogeneity [24] [25] . Both distant metastases [26] [27] nodal involvement [28] [29] and drug resistance [30] [31] [32] have been correlated with peculiar molecular signatures in PDAC. Cancer omics and biological signatures are able to stratify tumors depending on the cancer cell phenotype and the tumor niche, able to educate a neoplastic-friendly microenvironment for both solid and hematological cancer [33] [34] [35] [36] [37] . Resolving the spatial and clonal cancer heterogeneity, might provide fundamental clues able to deeper characterize translational target and oncogenic drivers, providing novel theragnostic targets.
The paradigm learned from colorectal carcinoma represents a pragmatic integration between biological prognostic factors and progressive resolution of comprehensive surgical-medical approach of metastatic colon carcinoma [38] [39] . The lesson from these evidences, drove expanded indication for surgery in metastatic neuroendocrine [40] and renal cell carcinoma [41] . On the other hand, current guidelines do not support surgical approach for PDAC in metastatic setting [5] .
To our knowledge this is the first report of coexistence of prolonged chemotherapeutic exposure along with clinical favorable outcome for a metastatic PDAC patient. He complained several mFOLFIRINOX related adverse events; nonetheless, we were able to administer more than 30 treatment cycles. Safety profile was acceptable in terms of supportive treatment. This multidimensional management displays paramount relevance, taking into account the frequent correlation between the length of treatment and the appearance of AE, which sometimes could require hospitalization [42] [43] . In frame of this thinking the need of optimal patient selection would prevent unnecessary and unethical treatment, bridging the gap of stratified approach dedicated to subjects harboring clinical and biological signatures that predict more favorable outcome when approached with combined strategies [44] [45] . 
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